<DOC>
	<DOCNO>NCT00351377</DOCNO>
	<brief_summary>Treatment immunosuppressive drug mycophenolate mofetil ( MMF ) may result gastrointestinal ( GI ) complication patient . This study 1 ) determine proportion patient autoimmune disease experience GI complaint MMF-based immunosuppressive treatment 2 ) ass switch MMF enteric-coated mycophenolate sodium ( EC-MPS ) result improve GI and/or health-related quality life outcome .</brief_summary>
	<brief_title>Gastrointestinal Health-related Quality Life Outcomes Patients With Autoimmune Diseases Treated With Mycophenolate</brief_title>
	<detailed_description />
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients autoimmune disease ; 2. receive immunosuppressive therapy include MMF time study enrollment ; 3. receive immunosuppressive regimen include MMF stable dose least 1 month prior enrollment . Patients enrol study expect treatment continue dose study end ( 68 week enrollment ) . Exclusion criterion : 1 . If applicable , GI symptom assume know caused Mycophenolic acid ( MPA ) therapy ( e.g . oral biphosphonates induce , infectious diarrhea ) ; 2 . Women childbearing potential planning become pregnant pregnant and/or lactate unwilling use effective mean contraception ; 3 . Presence psychiatric illness ( i.e. , schizophrenia , major depression ) , opinion site investigator , would interfere study requirement ; 4 . Current acute medical intervention hospitalization ; 5 . Presence medical condition relate GI event time visit , require immediate medical intervention . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Autoimmune disease , mycophenolate , GI problem</keyword>
</DOC>